Skip to main navigation
Skip to search
Skip to main content
University of Birmingham Home
Help & FAQ
Link opens in a new tab
Search content at University of Birmingham
Home
Research output
Profiles
Research units
Projects
Activities
Datasets
Equipment
Prizes
Press/Media
Targeting gp130 to prevent inflammation and promote insulin action
M J Kraakman
, T L Allen
,
M Whitham
, P Iliades
, H L Kammoun
, E Estevez
, G I Lancaster
, M A Febbraio
Research output
:
Contribution to journal
›
Review article
›
peer-review
21
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Targeting gp130 to prevent inflammation and promote insulin action'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Interleukin-6
100%
Inflammation
100%
Glycoprotein 130 (gp130)
100%
Insulin Action
100%
Metabolic Disease
42%
Obesity
28%
Rheumatoid Arthritis
14%
Liver
14%
Type 2 Diabetes Mellitus (T2DM)
14%
Western World
14%
Membrane Binding
14%
Skeletal muscle
14%
Disease-associated
14%
Monoclonal Antibody
14%
Adipose Tissue
14%
Crohn's Disease
14%
Insulin Sensitivity
14%
Receptor Complex
14%
Optimal Strategy
14%
Rheumatoid Arthritis Treatment
14%
Trans-signaling
14%
Unwanted Side Effects
14%
Low-grade Inflammation
14%
Metabolically Active
14%
Tocilizumab
14%
Pharmacology, Toxicology and Pharmaceutical Science
Interleukin 6
100%
Inflammation
100%
Glycoprotein Gp 130
100%
Diseases
42%
Receptor
28%
Cytokine
28%
Inflammatory Arthritis
28%
Rheumatoid Arthritis
28%
Side Effect
14%
Non Insulin Dependent Diabetes Mellitus
14%
Crohn's Disease
14%
Monoclonal Antibody
14%
Tocilizumab
14%
Metabolic Disorder
14%
Immunology and Microbiology
Interleukin 6
100%
Glycoprotein Gp 130
100%
Insulin
100%
Inflammatory Arthritis
28%
Cytokine
28%
Skeletal Muscle
14%
Monoclonal Antibody
14%
Insulin Sensitivity
14%
Adipose Tissue
14%
Crohn's Disease
14%
Tocilizumab
14%